{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-038061","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.166449+00:00","generated_at":"2026-05-15T08:00:53.956452+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track","bullets":["Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.","Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.","Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.","VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.","Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-038061","json":"https://secwatch.observer/filing/0001213900-26-038061.json","markdown":"https://secwatch.observer/filing/0001213900-26-038061.md","text":"https://secwatch.observer/filing/0001213900-26-038061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/ea0279571-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:00:53.956452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89b2b8e49dba2b8e7938ff9a99d4b00cebc6dbe4","claim":"Allarity Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.","evidence_excerpt":"On March 31, 2026, Allarity Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}